Diligence memo · auto-generated · as of July 3, 2026
K-PAX Pharmaceuticals, Inc.
K-PAX Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
K-PAX Pharmaceuticals, Inc. operates in Pharmaceuticals, based in MILL VALLEY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
K-PAX Pharmaceuticals, Inc. has raised $2.9M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.5M on 2013-01-31.
Most recent recorded round closed around 2013-01-31.
Valuation (modeled)modeled
Provath models K-PAX Pharmaceuticals, Inc. at approximately $56M (range $1.1M–$436M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.84× the median modeled value of Seed Pharmaceuticals companies in 2013–2015 (51 peers) — value vs value, same stage and era. Within the normal band (84% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 13.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 33% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 44% of those peers.
Closest niche peers: Assured Pharma, Inc., Wellesley Pharmaceuticals Llc, Generico, Llc, Aggamin Pharmaceuticals, LLC, Abeona Therapeutics LLC.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.